ZURICH: Novartis will price its new Mayzent multiple sclerosis drug at US$88,000 dollars per year, the Swiss company's head of pharmaceuticals, Paul Hudson, said.
Novartis said on Tuesday it had won U.S. Food and Drug Administration approval for Mayzent, as the company seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps two Alzheimer drug trials, wipes US$18 billion from market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Global IPO proceeds down 74% to US$13.1b in Q1 from year ago: EYONGOING geopolitical uncertainties dampened global IPO (initial public offering) activity in the first three months of this year, though a rebound is expected in the next quarter once the 'fog of uncertainty' clears, according to a quarterly IPO trends report by Ernst & Young (EY). Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »